Outlook Therapeutics resubmits ONS-5010 drug application to FDA after prior rejection

Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• high

  Company resubmitted Biologics License Application (BLA) for ONS-5010 to FDA on June 1, 2026. Resubmission follows earlier regulatory concerns, suggesting company has addressed FDA's prior objections. Approval would enable commercial sales.

  Item 8.01 Press Release verify on EDGAR →
• high

  BLA resubmissions typically occur after Complete Response Letters where FDA identifies deficiencies. Timeline to FDA decision typically ranges 6-10 months for resubmissions depending on review classification.

  8-K: Regulatory Filing verify on EDGAR →